We mainly observed that high DJ-1 expression group in HR+ subtype was associated with poor prognosis, low expression of chemokine receptor, high TMB, and more sensitivity to paclitaxel and docetaxel, highlighting the therapeutic potential and biomarker value of DJ-1 in HR+ breast cancer subtype. This evidence concerns the gene PARK7 and breast carcinoma.